These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11241312)

  • 1. DNA-synthesizing enzymes in breast cancer (thymidine kinase, thymidylate synthase and thymidylate kinase): association with flow cytometric S-phase fraction and relative prognostic importance in node-negative premenopausal patients.
    Romain S; Bendahl PO; Guirou O; Malmström P; Martin PM; Fernö M
    Int J Cancer; 2001 Jan; 95(1):56-61. PubMed ID: 11241312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer.
    Malmström P; Bendahl PO; Boiesen P; Brünner N; Idvall I; Fernö M;
    J Clin Oncol; 2001 Apr; 19(7):2010-9. PubMed ID: 11283134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic of DNA-synthesizing enzyme activities (thymidine kinase and thymidylate synthase) in 908 T1-T2, N0-N1, M0 breast cancers: a retrospective multicenter study.
    Romain S; Spyratos F; Descotes F; Daver A; Rostaing-Puissant B; Bougnoux P; Colonna M; Bolla M; Martin PM
    Int J Cancer; 2000 Sep; 87(6):860-8. PubMed ID: 10956398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer.
    Linderholm BK; Gruvberger-Saal S; Fernö M; Bendahl PO; Malmström P
    Breast; 2008 Oct; 17(5):484-91. PubMed ID: 18508268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy.
    Foekens JA; Romain S; Look MP; Martin PM; Klijn JG
    Cancer Res; 2001 Feb; 61(4):1421-5. PubMed ID: 11245445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
    Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG
    J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy.
    Cascinu S; Graziano F; Valentini M; Catalano V; Giordani P; Staccioli MP; Rossi C; Baldelli AM; Grianti C; Muretto P; Catalano G
    Ann Oncol; 2001 Feb; 12(2):239-44. PubMed ID: 11300331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidine kinase in epithelial ovarian cancer: relationship with the other pyrimidine pathway enzymes.
    Fujiwaki R; Hata K; Nakayama K; Moriyama M; Iwanari O; Katabuchi H; Okamura H; Sakai E; Miyazaki K
    Int J Cancer; 2002 May; 99(3):328-35. PubMed ID: 11992400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA-synthesis enzyme activity: a biological tool useful for predicting anti-metabolic drug sensitivity in breast cancer?
    Romain S; Martin PM; Klijn JG; van Putten WL; Look MP; Guirou O; Foekens JA
    Int J Cancer; 1997 Apr; 74(2):156-61. PubMed ID: 9133448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
    Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J; Christensen IJ; Briand P; Pappot H; Mouridsen HT; Blichert-Toft M; Danø K; Brünner N
    Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
    Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
    Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of uPA, PAI-1, and DNA content in adult renal cell carcinoma.
    Chautard D; Dalifard I; Chassevent A; Guyetant S; Daver A; Vielle B; Soret JY
    Urology; 2004 Jun; 63(6):1055-60. PubMed ID: 15183949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flow cytometric DNA ploidy defines patients with poor prognosis in node-negative breast cancer.
    Balslev I; Christensen IJ; Rasmussen BB; Larsen JK; Lykkesfeldt AE; Thorpe SM; Rose C; Briand P; Mouridsen HT
    Int J Cancer; 1994 Jan; 56(1):16-25. PubMed ID: 8262673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S-phase fraction determined on fine needle aspirates is an independent prognostic factor in breast cancer - a multivariate study of 770 patients.
    Gazic B; Pizem J; Bracko M; Cufer T; Borstnar S; Pohar-Marinsek Z; Us-Krasovec M
    Cytopathology; 2008 Oct; 19(5):294-302. PubMed ID: 18070112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of tumor biological factors on survival in node-negative breast cancer.
    Harbeck N; Dettmar P; Thomssen C; Henselmann B; Kuhn W; Ulm K; Jänicke F; Höfler H; Graeff H; Schmitt M
    Anticancer Res; 1998; 18(3C):2187-97. PubMed ID: 9703782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Standardization and quality control in the evaluation of proliferation parameters in T1T2, N0N1, M0 breast cancer : multicentric retrospective study I. DNA synthesis enzyme activities].
    Spyratos F; Romain S; Rostaing-Puissant B; Daver A; Collona M; Descotes F; Martin PM; Bougnoux P; Roth H; Bolla M
    Bull Cancer; 1999; 86(7-8):678-84. PubMed ID: 10477385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA flow cytometric analysis and prognosis of axillary lymph node-negative breast carcinoma.
    Bosari S; Lee AK; Tahan SR; Figoni MA; Wiley BD; Heatley GJ; Silverman ML
    Cancer; 1992 Oct; 70(7):1943-50. PubMed ID: 1525770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased activities of thymidylate synthetase and thymidine kinase in human thyroid tumors.
    Sakamoto S; Murakami S; Sugawara M; Mishima Y; Okamoto R
    Thyroid; 1991; 1(4):347-51. PubMed ID: 1841732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA flow cytometry and pathologic grading as prognostic guides in axillary lymph node-negative breast cancer.
    Merkel DE; Winchester DJ; Goldschmidt RA; August CZ; Wruck DM; Rademaker AW
    Cancer; 1993 Sep; 72(6):1926-32. PubMed ID: 8364870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.